Nathaniel Calloway - 01 Jun 2023 Form 4 Insider Report for LIFECORE BIOMEDICAL, INC. \DE\ (LFCR)

Reporting relationship: Director
Issuer ticker: LFCR
Reported as of: 01 Jun 2023
Net transaction value: $0
SEC form: 4
Accepted by SEC: 05 Jun 2023, 15:19:44 UTC
Prior SEC filing: 02 Feb 2023
Next SEC filing: 10 Jan 2024
Source filing: View source filing
Reporting owner signature: /s/ Rebecca Hilt, Attorney-In-Fact for Nathaniel Calloway

Key filing fact

Nathaniel Calloway filed Form 4 for LIFECORE BIOMEDICAL, INC. \DE\ (LFCR) on 05 Jun 2023.

Key facts

This page summarizes Nathaniel Calloway's Form 4 filing for LIFECORE BIOMEDICAL, INC. \DE\ (LFCR).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 05 Jun 2023, 15:19.

Change

Previous filing in this sequence was filed on 02 Feb 2023.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

LFCR transaction

Common Stock

Award

Transaction value
Shares: +18,182
Change %
Price
Shares after: 18,182
Date: 01 Jun 2023
Ownership: Direct
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis.

Footnote F2

Restricted Stock Units will vest and be settled on the earlier of the 1st anniversary of the grant date or the date of the 2024 Annual Meeting of Stockholders (provided such date is no less than 50 weeks from Grant Date).